TORONTO–( )–Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval associated with Cationorm ® Plus by Wellness Canada. Cationorm ® Plus is an unique hydrating artificial tear that restores moisture in the eye to provide long-lasting relief for dry eye and ocular allergy symptoms.

Dry out eye occurs when there is the problem with the tear film that normally keeps the particular eyes moist and lubricated. 1, 2, 3 Symptoms of dry vision include redness, burning, stinging, itching, sensitivity to light, and a feeling like something is within the eye. 4 It is estimated that about 21% of Canadians have dry eye, or about 6. 3 million people. 5 Ocular allergy involves inflammation of the conjunctiva, plus symptoms that can be seasonal or even year-round and may include itching, tearing, inflammation, and pain. six, 7, 8 Ocular allergies affect up to 1 in 5 people around the world. Both conditions can impact the quality of life for an individual, interfering with aspects of daily activities and work productivity. 9, 10, 11, 12, 13

“Millions associated with Canadians are impacted by the discomfort and potentially lifestyle-limiting symptoms associated with dry eye and ocular allergy. Artificial tears are considered the first-line treatment to relieve these symptoms, ” stated Craig Wallace, General Manager of North america, U. K., Ireland, plus South Africa at Santen. “We are usually pleased that will with this approval, doctors and patients within Canada will now benefit from the first synthetic tear that uses a positive cationic emulsion in order to provide improved hydration in the eye. The approval of Cationorm ® Plus is also a significant step forward in our ongoing growth in Europe and throughout North America. ”

Cationorm ® Plus will be a sterile, preservative-free, artificial tear containing the novel Novasorb ® technology. As the particular only synthetic tear that will uses positive cationic emulsion to hold hydration in place, Cationorm ® Plus protects, hydrates plus lubricates the eye while supporting the particular healing from the cornea (the transparent front part associated with the eye). Cationorm ® In addition is safe for daily use and restores the three layers of the particular tear movie on the eyes to offer relief from eye irritation and pain.

For more information plus instructions, please consult the product labeling, including packaging and inserts.

About Dry Eye and Ocular Allergy

Dry eye is an ocular condition with signs and symptoms such as redness, burning, stinging, itchiness, sensitivity to light, plus a feeling like something is in the eye. 4 Globally, dry eyes may affect as much as half the population. Each men and women can have dry attention, although it tends to impact more women. 14 Those of increased age, wearers of contact lenses, and those who frequently use computer or other digital screens are more likely to experience dry eyesight. 4 Dry eyes occurs when there is usually a problem with the tear film that normally keeps the eye moist plus lubricated, leading to inflammation and damage. Either tear fluid is no longer produced in sufficient quantity, the high quality of rip fluid has changed or the particular tear fluid evaporates too much. 1, 2, 3

Ocular allergic reaction involves inflammation of the conjunctiva, plus symptoms that will can be seasonal or year-round and may include itching, tearing, redness, plus pain. Ocular allergies influence up in order to 1 in 5 individuals around the world, and are most common in females. 6, 7, 8 Factors that may cause someone to experience a good ocular allergy include grasses, trees, fungal spore, dust mites, and animal dander. 15, 16 Having an ocular allergy increases a person’s risk of developing dry out eye. 17

Both conditions can impact the quality of existence for an individual, interfering along with aspects of every day activities plus work productivity. In severe cases, the particular conditions may even lead to visual damage. 9, 10, 11, 12, 13

Regarding Santen

As a global specialized company dedicated in order to eye health, Santen brings a more than 130-year history of scientific knowledge and organizational capabilities to research, development, plus commercialization associated with pharmaceutical, surgical, and OTC eye care products. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients within more compared to 60 countries. Santen provides products and services to contribute in order to the well-being of patients, their loved ones, plus consequently to society. For more information, please visit Santen’s websites , (North America headquarters) and (Japan headquarters).


1 Willcox MDP, et al. Ocul Surf 2017; 15(3): 366–403.

2 Wizert A, ainsi que al. PLoS ONE 2014; 9(3): e92461.

3 Daull P, ou al. J Ocul Pharmacol Ther 2020; 36(6): 355–365.

4 Messmer EM. Dtsch Arztebl Int 2015; 112: 71–82.

5 Caffery B, Srinivasan S, Reaume CJ, Fischer A, Cappadocia D, Siffel C, Chan CC. Prevalence of dry eye disease in Ontario, Nova scotia: A population-based survey. Ocul Surf. 2019 Jul; 17(3): 526-531. doi: 10. 1016/j. jtos. 2019. 02. 011. Epub 2019 Feb 27. PMID: 30825521.

6 Leonardi A, ain al. Curr Opin Allergic reaction Clin Immunol 2015; fifteen: 482 488.

7 La Rosa M, et al. Ital M Pediatr 2013; 39: 18.

8 Uchio E, tout autant que al. Graefes Arch Clin Exp Ophthalmol 2008; 246: 291–296.

nine Leonardi The, et ing. Clin Exp Immunol 2008; 153: 17–21.

10 Virchow JC, et al. L Med Econ 2011; 14: 305–314.

eleven Klossek JM, et ‘s. Int Arch Allergy Immunol 2012; 158: 411–417.

twelve McDonald Meters, et al. Ocul Surf 2016; 14(2): 144–167.

thirteen Verjee MA, et ing. Ophthalmol Ther 2020; 9: 877–888.

fourteen Stapleton F, et ‘s. Ocul Browse 2017; 15(3): 334–365.

15 Sacchetti Mirielle, et al. J Biol Regul Homeost Agents 2018; 32: 49–60.

16 College of Optometrists. Seasonal Allergic Conjunctivitis (Hay Fever Conjunctivitis); Perennial Sensitive Conjunctivitis. Available at: (accessed May 2022).

17 Villani E, et ing. Curr Opin Allergy Clin Immunol 2018; 18: 398–403.

Leave a Reply

Your email address will not be published. Required fields are marked *